

Chapter 8

References



Aaltomaa S, Lipponen P, Ala-Opas M, et al : Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. *Eur Urol* 39: 138-44, 2001.

Aaltomaa S, Lipponen P, Viitanen J, et al : Prognostic value of CD44 standard, variant isoforms 3 and 6 and –catenin expression in local prostate cancer treated by radical prostatectomy. *Eur Urol* 38: 555-62, 2000.

Adolfsson J : Deferred treatment of low-grade Stage T3 prostate cancer without distant metastases. *J Urol* 149: 326-9, 1993.

Adolfsson J, Carstensen J : Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. *J Urol* 146: 96-8, 1991.

Aihara M, Wheeler TM, Ohori M, et al : Heterogeneity of prostate cancer in radical prostatectomy specimens. *Urology* 43: 60-6;discussion 66-7, 1994.

Algebra F, Epstein JI, Aldape HC, et al : International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma. Assessment of prostate carcinoma in core needle biopsy – definition of minimal criteria for the diagnosis of cancer in biopsy material. *Cancer* 78: 367-81, 1996.

Allam CK, Bostwick DG, Hayes JA, et al : Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. *Mod Pathol* 9: 742-51, 1996.

Ambrosini G, Adida C, Altieri DC : A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. *Nature Med* 3: 917-21, 1997.

Anttila MA, Kosma V-M, Hongxiu J, et al : p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. *Br J Cancer* 79: 1870-8, 1999.

Arch R, Wirth K, Hofmann M, et al : Participation in normal immune responses of a metastasis-inducing splice variant of CD44. *Science* 257: 682-5, 1992.

Armstrong RC, Aja T, Xiang J, et al : Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. *J Biol Chem* 271: 16850-5, 1996.

Bahl R, Arora S, Nath N, et al : Novel polymorphism in p21^{WAF1/CIP1} cyclin dependent kinase inhibitor gene: association with human oesophageal cancer. *Oncogene* 19: 323-8, 2000.

Balbay MD, Pettaway CA, Kuniyasu H, et al : Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpress vascular endothelial growth factor. *Clin Cancer Res* 5: 783-9, 1999.

Baltaci S, Orhan D, Ozer G, et al : Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. *Br J Urol Int* 85: 155-9, 2000.

Barbareschi M, Caffo O, Doglioni C, et al : p21^{WAF1} immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB-1 expression, p53 gene and protein alterations and relapse-free survival. *Br J Cancer* 74: 208-15, 1996.

Bartolazzi BY, Peach R, Aruffo A, Stamenkovic I : Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumour development. *J Exp Med* 180: 53, 1994.

Bastacky SI, Walsh PC, Epstein JI : Relationship between perineural tumour invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. *Am J Surg Pathol* 17: 336-41, 1993.

Bauer J, Srivastava S, Connelly R, et al : Significance of family history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. *Urology* 51: 970-6, 1998.

Bigler SA, Deering RE, Brawer MK : Comparison of microscopic vascularity in benign and malignant prostate tissue. *Hum Pathol* 24: 220-6, , 1993.

Blute ML, Bergstralh EJ, Iocca A, et al : Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. *J Urol* 165: 119-25, 2001.

Boag AH, Young ID : Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. *Am J Pathol* 144: 584-91, 1993.

Böhm JP, Niskanen LK, Pirinen RT, et al : Reduced CD44 standered expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. *J Pathol* 192: 321-7, 2000.

Bonkhoff H : Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. *Prostate (suppl 8)*: 18-22, 1998.

Bonkhoff H, Remberger K : Differentiation pathways and histogenic aspects of normal and abnormal prostatic growth: a stem cell model. *Prostate* 28:98, 1996.

Boring CC, Squires TS, Health CW : Cancer statistics for African Americans. CA Cancer J Clin 42: 7, 1992.

Boring CC, Squires TS, Tong, et al : Cancer statistics. CA Cancer J Clin 44: 7-26, 1994.

Borre M, Bentzen SM, Nerström B, Overgaard J : Tumour cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 159: 1609-14, 1998.

Borre M, Høyer M, Sørensen FB, et al : Association between in vivo iododeoxyuridine labeling, MIB-1 expression , malignancy grade and clinical stage in human prostate cancer. APMIS 106: 389-95, 1998a.

Borre M, Stausbøl-Grøn B, Overgaard J : p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 164: 716-21, 2000.

Bostwick DG : Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18: 796-803, 1994a.

Bostwick DG : Grading prostate cancer. Am J Clin Pathol 102(suppl I): s38-56, 1994.

Bostwick DG : Prostate intraepithelial neoplasia. In Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 35-50, 1999.

Bostwick DG : Prostate intraepithelial neoplasia. In Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 43, 1999a.

Bostwick DG, Amin MB, Dundore P, et al : Architectural patterns of high-grade prostatic intraepithelial neoplasia. *Human Pathol* 24:298-310, 1993.

Bostwick DG, Brawer MK : prostatic intraepithelial neoplasia and early invasion in prostate cancer. *Cancer* 59: 788-94, 1987.

Bostwick DG, Cooner WH, Denis L, et al : The association of benign Prostatic hyperplasia and cancer of the prostate. *Cancer* 70(suppl): 291-301, 1992.

Bostwick DG, Devaraj L : Basal cell proliferations and tumours of the prostate. In: *Pathology of the prostate* (Foster C, Bostwick DG, eds). WB Saunders: Philadelphia, PA: 157-71, 1998.

Bostwick DG, Dousa M, Crawford B, et al : Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. *Am J Surg Pathol* 18: 1240-6, 1994.

Bostwick DG, Foster CS : Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumour Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. *Semin Urol Oncol* 17: 222-72, 1999.

Bostwick DG, Foster CS, Algaba F, et al : Prostate tissue factors. In: *Murphy G, Denis L, Khoury S, et al(eds). Prostate cancer: Second International Consultation on Prostate Cancer*. Plymouth: Plymbridge Distributors: 162-201, 2000a.

- Bostwick DG, Grignon DJ, Hammond ME, et al :** Prognostic factors in prostate cancer. College of American Pathologists Consensus statements 1999. Arch Pathol Lab Med 124: 995-1000, 2000.
- Bostwick DG, Leske DA, Qian J, Sinha AA:** Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Pathol Res Pract 191:850-5, 1995.
- Bostwick DG:** High-grade prostatic intraepithelial neoplasia: the most likely precursor of prostate cancer. Cancer 75:1823-36, 1995.
- Bourguignon L, Lokeshwar V, Chen X, et al :** Hyaluronic acid induced lymphocyte signal transduction and HA receptor(GP85/CD44)-cytoskeleton interaction. J Immunol 151: 6634-44, 1993.
- Bratt O :** Hereditary prostate cancer. BJU Int 85: 588-98, 2000.
- Brawer MK, Crawford ED, Fowler J, et al :** Prostate cancer: epidemiology and screening. Rev Urol (suppl): 5-9, 2000.
- Brinkmann AO, Jenster G, Ris-Staplers C, et al:** Androgen receptor mutations. J Steroid Biochem Mol Biol 53:443, 1995.
- Brooks JD, Metter EJ, Chan DW, et al :** Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166: 2034-8, 2001.
- Brown C, Sauvageot J, Kahane H, Epstein JI :** Cell proliferation and apoptosis in prostate cancer-correlation with pathologic stage?. Mod Pathol 9: 205, 1996.
- Brown DC, Gatter KC :** Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503, 1990.
- Bubendorf L, Sauter G, Moch H, et al :** Ki67 labeling index An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178: 437-41, 1996.

Bubendorf L, Tapia C, Gasser TC, et al : Ki67 labeling index in core needle biopsies independently predicts tumour-specific survival in prostate cancer. *Hum Pathol* 29: 949-54, 1998.

Burton JL, Oakley N, Anderson JB: Recent advances in the histopathology and molecular biology of prostate cancer. *BJU Int* 85: 87-94, 2000.

Byrne RL, Horne CHW, Robinson MC, et al : The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. *Br J Urol* 79: 190-5, 1997.



Carter BS, Bova GS, Beaty TH, et al : Hereditary prostate cancer: epidemiologic and clinical features. *J Urol* 150: 797-802, 1993.

Carter BS, Ewing CM, Ward WS, et al : Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proc Natl Acad Sci* 87: 8715, 1990.

Carter HB, Sauvageot J, Walsh PC, Epstein JI : Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. *J Urol* 157: 2206-9, 1997.

Casella R, Bubendorf L, Sauter G, et al : Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. *J Urol* 160: 406-10, 1998.

Catlett-Falcone R, Landowski TH, Oshiro MM, et al : Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. *Immunity* 10: 105-15, 1999.

Cattoretti G, Becker MHG, Key Goran, et al : Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. *J Pathol* 168: 357-63, 1992.

Chan J, Stampfer MJ, Giovannucci E, et al : Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. *Science* 279: 563-6, 1998.

Chang JJ, Shinohara K, Hovey R, et al : Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. *Urology* 52: 89-93, 1998.

Chang B-D, Broude EV, Fang J, et al : p21^{WAF1/CIP1/Sdi1}-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. *Oncogene* 19: 2165-70, 2000.

Chen Z, Chen H, Stamey TA : Monoclonal antibodies 2F5 and 4G10 against prostate-specific antigen (PSA) complexed to α 1-antichymotrypsin. *J Urol* 160: 870-5, 1998.

Cheng L, Cheville JC, Pisansky TM, et al : Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. *Am J Surg Pathol* 23(7): 803-8, 1999.

Cher ML, Bova GS, Moore DH, et al : Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. *Cancer Res* 56: 3091, 1996.

Cheville JC, Reznicek MJ, Bostwick DG : The focus of "Atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice. *Am J Clin Pathol* 108: 633-40, 1997.

Chodak GW, Thisted RA, Gerber GS, et al : Results of conservative management of localized prostate cancer. *N Engl J Med* 330: 242, 1994.

- Chung LW, Davies R** : Prostate epithelial differentiation is directed by its surrounding stroma. *Mol Biol Rep* 23: 13, 1996.
- Cina SJ, Epstein JI** : Adenocarcinoma of the prostate with atrophic features. *Am J Surg Pathol* 21: 289-95, 1997.
- Clem RJ, Cheng EH, Karp CL, et al** : Modulation of cell death by Bcl-xl through caspase interaction. *Proc Natl Acad Sci USA* 95: 554-9, 1998.
- Clem RJ, Miller LK** : Control of programmed cell death by the baculovirus genes p35 and IAP. *Mol Cell Biol* 14: 5212-22, 1994.
- Cohen JJ** : Apoptosis. *Immunol Today* 14: 126-30, 1993.
- Cohen RJ, McNeal JE, Bailliet T** : Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: Significance for cancer progression. *Prostate* 43(1): 11-9, 2000.
- Coley CM, Barry MJ, Fleming C, Albert G** : Early detection of prostate cancer: part I: prior probability and effectiveness of tests. *Ann Intern Med* 126: 394, 1997.
- Colombel M, Symmans F, Gil S, et al** : Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. *Am J Pathol* 143: 390-400, 1993.
- Conrad P, Rothman B, Kelley K, et al** : Mechanism of peripheral T cell activation by coengagement of CD44 and CD44. *J Immunol* 149: 1833-9, 1992.
- Comin CE, Anichini C, Boddi V, et al** : MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. *Histopathology* 36: 26-31, 2000.
- Cookson MS, Fleshner NE, Soloway SM, Fair WR** : Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. *J Urol* 157: 559-62, 1997.

Corder EH, Guess HA, Hulka BS, et al : Vitamin D and prostate cancer: a prediagnostic study with stored sera. *Cancer Epidemiol Biomarkers Prev* 2: 467, 1993.

Cress AE, Rabinovitz I, Zhu W, Nagle RB : The $\alpha 6\beta 1$ and $\alpha 6\beta 4$ integrins in human prostate cancer progression. *Cancer Metastasis Rev* 14: 219, 1995.

Cross SS : Grading and scoring in histopathology. *Histopathology* 33: 99-106, 1998.

Cude KJ, Dixon SC, Guo Y, et al : The androgen receptor : genetic considerations in the development and treatment of prostate cancer. *J Mol Med* 77: 419-26, 1999.

Cuhna GR, Foster B, Thomson A, et al: Growth factors as mediators of androgen action during development of the male urogenital tract. *World J Urol* 13:264,1995.

Cuhna GR, Hayward SW, Dahiya R, Foster BA: Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. *Acta Anat (Basel)* 155:63,1996.

Culig Z, Hobisch A, Hittmair A, et al : Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. *Prostate* 35: 63-70, 1998.

Cupp MR, Bostwick DG, Myers RP, Oesterling JE : The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. *J Urol* 153: 1543-8, 1995. *



D'Amico AV, Whittington R, Malkowicz SB, et al : A multivariate analysis of clinical and pathological factors that predict for prostate-specific antigen failure after radical prostatectomy for prostate cancer. *J Urol* 154: 131, 1995.

- Daniel L, Lechevallier E, Giorgi R, et al** : CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinoma. *J Pathol* 193: 345-9, 2001.
- Darai E, Combrouze FW, Fauconnier A, et al** : Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: comparison with cystadenomas and overt carcinomas. *Histopathology* 32: 151-9, 1998.
- Davidson D, Bostwick DG, Qian J, et al** : Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. *J Urol* 154: 1295-9, 1995.
- De La Torre, Haggman M, Brandstedt S, et al** : Prostatic intraepithelial neoplasia and invasive carcinoma in total prostatectomy specimens: distribution, volume and DNA ploidy. *Br J Urol* 72:207-13 , 1993.
- De Marzo AM, Bradshaw C, Sauvageot J, et al** : CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. *Prostate* 34: 162-8, 1998.
- de Vere White RW, Deitch AD, Jackson AG** : Radical differences in clinically localized prostate cancers of black and white men. *J Urol* 159: 1979-83, 1998.
- Dersimonian R, Clemmens J, Spirtas R, et al** : Vasectomy and prostate cancer risks: methodological review of the evidence. *J Clin Epidemiol* 46: 163, 1993.
- Deschenes J, Weidner N** : Nucleolar organizer regions (NOR) in hyperplastic and neoplastic prostate disease. *Am J Surg Pathol* 14: 1148-55, 1990.
- Deveraux QL, Takahashi R, Salvesen GS, et al** : X-linked IAP is a direct inhibitor of cell-death proteases. *Nature* 388: 300-3, 1997.

- di Sant'Agnese PA* : Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate (suppl 8): 74-9, 1998.
- Diaz JJ, Mora LB, Austin PF, et al* : Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoural cell proliferation. Urology 53: 931-8, 1999.
- Diaz JJ, Pow-Sang JM, Mora LB, et al* : Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol 5: 149-54, 2000.
- Dietrick DD, McNeal JE, Stamey TA* : Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume . Urology 45: 987-92, 1995.
- Dillioglulil O, Miles BJ, Scardino PT*: Current controversies in management of localized prostate cancer. Europ Urol 28: 85, 1995.
- DiPaola RS, Kumar P, Hait WN, et al* : State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey. N J Med 98: 23-33, 2001.
- Doesburg P, Kuil CW, Berrevoets CA, et al* : Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand-binding domain of the androgen receptor. Biochemistry 36: 1052-64, 1997.
- Dong JT, Lamb PW, Rinker-Schaeffer CW, et al* : KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884, 1995.
- Dong JT, Suzuki H, Pin SS, et al* : Down-regulation of the KAI1 metastasis suppressor gene during progression of human prostatic cancer infrequently involves mutation or allelic loss. Cancer Res 56: 4387, 1996.

Duggan JA, Bostwick DG, Myers RP, et al : The definition of preoperative prediction of clinically insignificant prostate cancer. J Am Med Assoc 275: 288-94, 1996.

Dunsmuir WD, Gillett CE, Meyer LC, et al : Molecular markers for predicting prostate cancer stage and survival. Br J Urol Int 86: 869-78, 2000.

Duque JL, Loughlin KR, Adam RM, et al : Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523-7, 1999.



Egan AJ, Bostwick DG : Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 21: 1496-1500, 1997.

Eissa S, Shoman S : Tumour Markers 2nd ed. London: Chapman & Hall Publishers: 133, 1998a.

Eissa S, Shoman S : Tumour Markers 2nd ed. London: Chapman & Hall Publishers: 131-144, 1998.

Ekman P, Adolfsson J, Gronberg H : The natural history of prostate cancer. In Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 1-16, 1999.

El-Bolkainy MN : Topographic Pathology of Cancer, NCI, Cairo University, 2000.

EL-Deiry WS, Harper JW, O'Conner PM, et al : WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-74, 1994.

El-Deiry WS, Tokino T, Waldman T, et al : Topological control of p21^{WAF1/CIP1} expression in normal and neoplastic tissues. *Cancer Res* 55: 2910-9, 1995.

El-Deiry WS, Tokino T, Velculescu VE, et al : WAF1, a potential mediator of p53 tumour suppression. *Cell* 75: 817-25, 1993.

Elgamal AA, van Poppel HP, Van de Voorde WM, et al : Impalpable invisible stage T1c prostate cancer : characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. *J Urol* 157:244-50, 1997.

Engelstein D, Mukamel E, Cytron S, et al : A comparison between digitally-guided fine needle aspiration and ultrasound-guided transperineal core needle biopsy of the prostate for the detection of prostate cancer. *Br J Urol* 74: 210-3, 1994.

Epstein JI : Incidence and significance of positive margins in radical prostatectomy specimens. *Urol Clin N Am* 23: 651-63, 1996.

Epstein JI, CarMichael M, Walsh PC : Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation to tumour, grade, and margins of resection to prognosis. *J Urol* 149: 1040-5, 1993.

Epstein JI, Grignon DJ, Humphrey PA, et al : Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. *Am J Surg Pathol* 19: 873-86, 1995.

Epstein JI, Partin AW, Sauvageot J, Walsh PC : Prediction of progression following radical prostatectomy . *Am J Surg Pathol* 20: 286-92, 1996.

Epstein JI, Sauvageot J : Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression? *J Urol* 157: 241-3, 1997.

Epstein JI, Walsh PC, Sauvageot J, Carter HB : Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 158: 1886-90, 1997.

Epstein JI, Wojno KJ : The prostate and seminal vesicles. In Sternberg SS ed. Diagnostic Surgical Pathology, 3rd ed. Philadelphia: Lippincott Williams&Wilkins:1893-942, 1999.

Epstein JI, Potter SR : The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 166: 402-10, 2001.

Even G, Harrington E, Fanidi A, et al : Integrated control of cell proliferation and cell death by the c-myc oncogene. Roy Soc Lond B Biol Sci 345: 269-75, 1994.

Ewing CM, Ru N, Morton RA, et al : Chromosome 5 suppresses tumourigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 55: 4813, 1995.

F

Fernandes A, Hamburger AW, Gerwin BI : ErbB-2 kinase is required for constitutive Stat3 activation in malignant human lung epithelial cells. Int J Cancer 83: 564-70, 1999.

Fero ML, Rivkin M, Tasch M, et al : A syndrome of multiorgan hyperplasia with features of gigantism, tumourigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-44, 1996.

Ferrer FA, Miller LJ, Andrawis RJ, et al : Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51:161-7, 1998.

Fichtner J : The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU Int 86: 181-90, 2000.

- Fidler IJ, Ellis LM** : The implications of angiogenesis for the biology and therapy of cancer metastasis. *Cell* 79: 185-8, 1994.
- Figueroa JA, De Raad S, Tadlock L, et al** : Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. *J Urol* 159: 1379-83, 1998.
- Fleshner NE, Fair WR** : Indications for transition zone biopsy in the detection of prostatic carcinoma. *J Urol* 157: 556-8, 1997.
- Foekens JA, Dall P, Klijn JGM, et al** : Prognostic value of CD44 variant expression in primary breast cancer. *Int J Cancer (Pred Oncol)* 84: 209-15, 1999.
- Folkman J** : Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1: 27-31, 1995a.
- Folkman J** : Clinical applications of research on angiogenesis. *N Engl J Med* 333: 1757-63, 1995.
- Fong CJ, Sherwood ER, Braun EJ, et al** : Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. *Prostate* 21: 121, 1992.
- Ford D, Easton DF, Bishop DT, et al** : Risks of cancer in BRCA-1 carriers. *Lancet* 343: 692, 1994.
- Fornaro M, Tallini G, Bofetiado CJ, et al** : Down-regulation of β 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. *Am J Pathol* 149: 765, 1996.
- Fortier AH, Nelson BJ, Grella DK, Holaday JW** : Antiangiogenic activity of prostate-specific antigen. *J Natl Cancer Inst* 91: 1635-40, 1999.
- Fox S, Fawcett J, Jackson D, et al** : Normal human tissues, in addition to some tumours, express multiple different CD44 isoforms. *Cancer Res* 54: 4539-46, 1994.

Fredersdorf S, Milne AW, Hall PA, et al : Characterization of a panel of novel anti-p21^{WAF1/CIP1} monoclonal antibodies and immunohistochemical analysis of p21^{WAF1/CIP1} expression in normal human tissues. *Am J Pathol* 148: 825-35, 1996.

Frisch SM, Francis H : Disruption of epithelial cell-matrix interactions induces apoptosis. *J Cell Biol* 124: 619-26, 1994.

Fujikawa K, Matsui Y, Kobayashi T, et al : Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume. *J Urol* 164: 1587-90, 2000.

Funk JO, Waga S, Harry JB, et al : Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. *Genes Dev* 11: 2090-100, 1997.

Furutani M, Arii S, Tanaka H, et al : Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. *Cancer Lett* 111: 191-7, 1997.

Furuya Y, Krajewski S, Epstein JI, et al : Expression of bcl-2 and the progression of human and rodent prostatic cancers. *Clin Cancer Res* 2: 389-98, 1996.

G

Gainnulis I, Montironi R, Galluzzi CM, et al : Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN). *Anticancer Res* 13: 2447-52, 1993.

Gallagher T : The protein and proteoglycan guises of Hermes/CD44. *Glycobiology* 2: 93-7, 1992.

Gao AC, Lou W, Sleeman JP, Isaacs JT : Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. *Cancer Res* 58: 2350-2, 1998.

Gao M, Ossowski L, Ferrari AC : Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in

androgen-dependent LNCaP cells and their androgen-independent derivative. *J Cell Physiol* 179: 336-46, 1999.

Gao X, Chen YQ, Wu N, et al : Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. *Oncogene* 11: 1395-8, 1995.

Gao X, Honn KV : Recessive oncogenes: current status. *Pathol Oncol Res* 1: 7-22, 1995.

Garcia R, Bowman TL, Niu G, et al : Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. *Oncogene* 20: 2499-513, 2001.

Gately S, Twardowski P, Stack MS, et al : Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. *Cancer Res* 56: 4887-90, 1996.

Geldof AA : Models of skeletal metastasis: a reappraisal of Batson's plexus. *Anticancer Res* 17(3A): 1535, 1997.

Gerdes J, Becker MHG, Key G, et al : Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues[letter]. *J Pathol* 174: 1685-7, 1992.

Gerschenson LE, Rotello RJ : Apoptosis: a different type of cell death. *FASEB J* 6: 2450-5, 1992.

Getzenberg RH, Pienta KJ, Coffey DS : The tissue matrix: cell dynamics and hormone action. *Endocrine Rev* 11: 399-417, 1990.

Gilliland FD, Gleason DF, Hunt WC, et al : Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. *J Urol* 165: 846-50, 2001.

Giovannucci E : How is individual risk for prostate cancer assessed?. *Hematol Oncol Clin North Am* 10: 537, 1996.

- Giovannucci E, Stampfer MJ, Krithivas K, et al :** The CAG repeat within the androgen receptor and its relationship to cancer. *Proc Natl Acad Sci USA* 94: 3320, 1997.
- Giovannucci E, Stampfer MJ, Chun A, et al :** CAG repeat within the androgen receptor gene: an incidence of surgery for benign prostatic hyperplasia in U.S. physicians. *Prostate* 39: 130, 1999.
- Gleason DF, Mellinger GT, The Veterans Administration Cooperative Urological Research Group :** Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Urol* 167: 935-8, 2002.
- Gleason DF:** Atypical hyperplasia, benign hyperplasia, and well-differentiated adenocarcinoma of the prostate. *AM J Surg Pathol* 9: 53, 1985.
- Gleason DF:** Histologic grading of prostate cancer: a perspective. *Hum Pathol* 23: 273-9, 1992.
- Gleason DF:** Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. *Urol* 47: 289-91, 1996.
- Goldenberg SL, Bruchovsky N, Gleave ME, et al :** Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. *Urology* 45: 839-45, 1995.
- Granberg D, Wilander E, Oberg K, Skogseid B :** Decreased survival in patients with CD44-negative typical bronchial carcinoid tumours. *Int J Cancer (Pred Oncol)* 84: 484-8, 1999.
- Green GF, Kitadai Y, Pettaway CA, et al :** Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. *Am J Pathol* 150: 1571-82, 1997.

Greene DR, Fitzpatrick JM, Scardino PT: Anatomy of the prostate and distribution of early prostate cancer. *Semin Surg Oncol* 11:9, 1995.

Greenlee RT, Murray T, Bolden S, Wingo PA: cancer statistics, 2000, *CA Cancer J Clin* 50:7, 2000.

Griffiths K, Coffey DS, Cockett ATK, et al : The regulation of prostatic growth. In: *The Third International Consultation on BPH* (Cockett ATK, Khoury S, Aso Y, et al, eds). *SCI: Paris* : 71-115, 1996.

Griffiths K, Morton MS : Aspects of the cell biology of prostate cancer. In *Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 53-54, 1999a.*

Griffiths K, Morton MS : Aspects of the cell biology of prostate cancer. In *Kaisary AV, Murphy GP, Denis L, Griffiths K eds. Text book of prostate cancer pathology, diagnosis and treatment. London: Martin Dunitz Ltd: 51-74, 1999.*

Grignon DJ, Caplan R, Sarkar FH, et al : p53 status and prognosis of locally advanced prostatic carcinoma: a study based on RTOG 8610. *J Natl Cancer Inst* 89:158, 1997.

Günthert U, Hofmann M, Rudy W, et al : A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. *Cell* 65: 13-24, 1991.

Guo Y, Sklar GN, Borkowski A, et al : Loss of the Cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumour grade. *Clin Cancer Res* 3(12 pt 1): 2269-74, 1997.

Hampel OZ, Kattan MW, Yang G, et al : Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. *J Urol* 159: 2220-5, 1998.

- Han M, Snow PB, Epstein JI, et al** : A neural network predicts progression for men with Gleason score 3+7 versus 4+3 tumours after radical prostatectomy. *Urology* 56: 994, 2000.
- Hanahan D, Christofori G, Naik P, Arbeit J** : Transgenic mouse models of tumour angiogenesis: the angiogenic switch , its molecular controls, and prospects for preclinical therapeutic models. *Eur J Cancer* 32A: 2386-93, 1996.
- Hanahan D, Folkman J** : Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. *Cell* 86: 353-64, 1996.
- Hanks GE, D'Amico A, Epstein BE, et al** : Prostate-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumour doubling time. *Int J Rad Oncol Biol Phys* 27: 125-7, 1993.
- Haq M, Goltzmann D, Tremblay G, Brodt P** : Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. *Cancer Res* 52: 4613-9, 1992.
- Hart IR** : 'Seed, and soil' revisited: mechanisms of site-specific metastasis. *Cancer Metastasis Rev* 1: 5-16, 1982.
- Hartwell LH, Kastan K-H** : Cell cycle control and cancer. *Science* 226: 1821-8, 1994.
- Haussler O, Epstein JI, Amin MB, et al** : Cell proliferation, apoptosis, oncogene, and tumour suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. *Hum Pathol* 30(9): 1077-86, 1999.
- Heidtmann HH, Nettelbeck DM, Mingels A, et al** : Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. *Br J Cancer* 81: 1269-73, 1999.

- Hengartner MO, Horvitz HR** : C. elegans cell survival gene ced-9 encodes a functional homologue of the mammalian proto-oncogene bcl-2. *Cell* 76: 665-76, 1994.
- Henkart PA** : ICE family proteases: mediators of all apoptotic cell death. *Immunity* 4: 195-201, 1996.
- Henricks WH, England BG, Giacherio DA, et al** : Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. *Am J Clin Pathol* 109: 533-9, 1998.
- Henson DE, Hutter RVP, Farrow G, et al** : Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. *Arch Pathol Lab Med* 118: 779-83, 1994.
- Hepburn PJ, Griffiths K, Harper ME** : Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro. *Prostate* 33: 123-32, 1997.
- Hermanek P, Sobin LH (eds)**, TNM Classification of Malignant Tumours, 4th edn, 2nd rev. Springer-Verlag: New York, 1992.
- Hirano D, Werahera PN, Crawford ED, et al** : Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumour volume, grade, tumour doubling time and life expectancy. *J Urol* 159:1265-9, 1998.
- Hobeika AC, Etienne W, Cruz PE, et al** : IFN γ induction of p21 WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. *Int J Cancer* 77: 138-45, 1998.
- Hockenbery DM, Oltvai ZN, Yin X, et al** : Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 75: 241-51, 1993.
- Hogan BL** : Bone morphogenic proteins in development. *Curr Opin Genet Devel* 6: 432, 1996.

Holm R, Skovlund E, Skomedal H, et al : Reduced expression of p21^{WAF1} is an indicator of malignant behaviour in anal carcinomas. *Histopathology* 39: 43-9, 2001.

Howie BJ, Shultz TD : Dietary and hormonal interrelationships among vegetarian Seventh-Day Adventist and nonvegetarian men. *Am J Clin Nutr* 42: 127, 1985.

Hseih J-T, Luo W, Song W : Tumour suppressive role of androgen regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma revealed by sense and antisense approaches. *Cancer Res* 55: 190, 1995.

Hu WL, Li YQ, He HX, et al : KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese. *Asian J Androl* 2: 221-4, 2000.

Hui AM, Kanai Y, Sakamoto M, et al : Reduced p21 (WAF1/CIP1) expression and p53 mutations in hepatocellular carcinomas. *Hepatology* 25: 575-9, 1997.

Humphrey PA, Vollmer RT, Ackerman LV : Percentage carcinoma as a measure of prostatic tumour size in radical prostatectomy tissues. *Mod Pathol* 10: 326-33, 1997.

Hunter T, Pines J : Cyclins and cancer II: cyclin D and CDK inhibitors come of age. *Cell* 79: 573-82, 1994.

Huuhtanen RL, Blomqvist CP, Wiklund TA, et al : Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. *Br J Cancer* 79: 945-51, 1999.

Iczkowski KA, Bassler TJ, Schwob VS, et al : Diagnosis of 'suspicious for malignancy' in prostate biopsies: predictive value for cancer. *Urology* 51: 749-58, 1998.

Ingles SA, Coetzee GA, Ross RK, et al : Association of prostate cancer with vitamin D receptor haplotypes in African Americans. *Cancer Res* 58: 1620-3, 1998.

Ingles SA, Ross RK, YU MC, et al : Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. *J Natl Cancer Inst* 89: 166, 1997.

Inoue K, Slaton JW, Eve BY, et al : Interleukin-8 expression regulates tumourigenicity and metastases in androgen-independent prostate cancer. *Clin Cancer Res* 6: 2104-19, 2000.

Irvine RA, Yu MC, Ross RK, Coetze GA : The CAG and GGC microsatellites of the androgen receptor gene in linkage disequilibrium in men with prostate cancer. *Cancer Res* 55: 1937-40, 1995.

Ito K, Sasano H, Matsunga G, et al : Correlation between p21 expression and clinico-pathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinomas. *J Pathol* 183: 318-24, 1997.

Izawa JJ, Dinney CPN : The role of angiogenesis in prostate and other urologic cancers: a review. *CMAJ* 164(5): 662-70, 2001.

Jacob K, Webber M, Benayahu D, Kleinman HK : Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. *Cancer Res* 59: 4453-7, 1999.

Jarmulowicz MR : The role of pathology in biopsy, diagnosis, and management of prostate cancer. In Kaisary AV, Murphy GP, Denis L, Griffiths K eds. *Text book of prostate cancer pathology, diagnosis and treatment*. London: Martin Dunitz Ltd: 17-33, 1999.

Jenster G : Ligand-independent activation of the androgen receptor by growth factors and cytokines. *J Pathol* 191: 227-8, 2000.

Jiang W : In vitro models of cancer invasion and metastasis: recent developments. Eur J Surg Oncol 20: 493-9, 1994.

Johansson J-E, Adami H-O, Anderson S-O, et al : High 10-year survival rate in patients with early untreated prostatic cancer. J Am Med Assoc 267: 2191-6, 1992.

Johansson JE, Holmberg L, Johansson S, et al : Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. J Am Med Assoc 277: 467-71, 1997.

Jones a, Fujiyama C, Turner K, et al : Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis. Br J Urol Int 86: 80-6, 2000.

Josef IB, Nelson JB, Denmeade SR, Isaacs JT : Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3: 2507-11, 1997.

 **Kaleem Z Swanson PE, Vollmer RT, Humphrey PA** : Prostatic adenocarcinoma with atrophic features. A study of 202 consecutive completely embedded radical prostatectomy specimens . Am J Clin Pathol 109: 695-703, 1998.

Kallakury BV, Sheehan CE, Ambros RA, et al : Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 16: 1302-9, 1998.

Kallakury BVS, Yang F, Figge J, et al : Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumour grade and ploidy. Cancer 78: 1461-9, 1996.

Karayi MK, Neal DE, Markham AF : Current status of linkage studies in hereditary prostate cancer. BJU. Int 86: 659-69, 2000.

- Kerr JFR, Winterford CM, Harmon BV** : Apoptosis: its significance in cancer and cancer therapy. *Cancer* 73: 2013-26, 1994.
- Keshgegian AA, Johnson E, Cnaan A** : Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. *Am J Clin Pathol* 110: 443-9, 1998.
- Kim IY, Ahn HJ, Zelner DJ, et al** : Expression and localisation of transforming growth factor- β receptors type I and type II in the rat ventral prostate during regression. *Mol Endocrinol* 10: 107-15, 1996.
- Kleinerman Di, Troncoso P, Lin SH, et al** : Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumour suppressor. *Cancer Res* 55: 1215, 1995.
- Koivisto P, Visakorpi T, Kallioniemi OP** : Androgen receptor gene amplification : a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. *Scand J Clin Lab Invest Suppl* 226: 57, 1996.
- Kolonel LN** : Nutrition and prostate cancer. *Cancer Causes Control* 7: 83, 1996.
- Koopman G, Heider K-H, Host E, et al** : Activated human lymphocytes and aggressive non-hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. *J Exp Med* 177: 897-904, 1993.
- Kostenuik PJ, Singh G, Orr FW** : Transforming growth factor beta upregulates integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. *Clin Exp Metastasis* 15: 41, 1997.
- Krajewska M, Wang G, Krajewska S, et al** : Immunohistochemical analysis of in vivo patterns of expression of CCP32 (caspase-3), a cell death protease. *Cancer Res* 57: 1605-13, 1997.

- Kruger EA, Blagosklonny MV, Dixon SC, Figg WD** : UCN-01 , a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response. *Invasion Metastasis* 18: 209-18, 2000.
- Kubota Y, Fujinami K, Uemura H, et al** : Retinoblastoma gene mutations in primary human prostate cancer. *Prostate* 27: 314-20, 1995.
- Kucuk O, Sarkar FH, Sakr WA, et al** : Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Cancer Epidemiol Bio-markers Prev* 10: 861-8, 2001.
- Kuller LH** : Dietary fat and chronic diseases: epidemiologic overview. *J Am Diabet Assoc* 97: 59, 1997.
- Kumar R, Fidler IJ** : Angiogenic molecules and cancer metastasis. *In Vivo* 18: 27-34, 1998.
- Kupelain P, Kupelain V, Witte J, et al** : Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. *J Clin Oncol* 15: 1478-80, 1997.
- Kwabi-Addo B, Giri D, Schmidt K, et al** : Haploinsufficiency of the Pten tumour suppressor gene promotes prostate cancer progression. *Proc Natl Acad Sci USA* 98: 11563-8, 2001.
- La Spada AR, Wilson EM, Lubahn DB, et al** : Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* 352: 77, 1991.
- Lalani E-N, Laniado ME, Abel PD** : Molecular and cellular biology of prostate cancer. *Cancer Metastasis Rev* 16:29, 1997.
- Lang SH, Clarke NW, George NJ, Testa NG** : Primary prostatic epithelial cell binding to human bone marrow stroma and the role of $\alpha 2 \beta 1$ integrin. *Clin Exp Metastasis* 15: 218, 1997.

- Lang SH, Miller WR, Habib FK** : Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow. *Prostate* 27: 287-93, 1995.
- Latil A, Cussenot O, Fournier G, et al** : Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. *Cancer Res* 57: 1058, 1997.
- Lau WK, Blute ML, Bostwick DG, et al** : Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. *J Urol* 166: 1692-7, 2001.
- Layfield LI, Goldstein NS** : Morphometric analysis of borderline atypia in prostatic aspiration biopsy specimen. *Anal Quant Cytol Histol* 13: 288-92, 1991.
- Lee C, Sutkowski DM, Sensibar JA, et al** : Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cell line LNCaP, by dihydrotestosterone. *Endocrinology* 137: 991-9, 1995.
- Lehr JE, pienta KJ** : Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. *J Natl Cancer Inst* 90: 118-23, 1998.
- Lesley J, He Q, Miyake K, et al** : Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. *J Exp Med* 175: 257-66, 1992.
- Lesley J, Kincade P, Hyman R** : Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding of antibody. *Eur J Immunol* 23: 1902-9, 1993.

- Lessells AM, Burnett RA, Howatson SR, et al** : Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. *Hum Pathol* 28: 646-9, 1997.
- Levine AC, Liu XH, Greenberg PD, et al** : Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. *Endocrinology* 139: 4672-8, 1998.
- Levine AJ** : p53, the cellular gatekeeper for growth and division. *Cell* 88: 323-31, 1997.
- Li X, Hui A-M, Shi Y-Z, et al** : Reduced p21^{WAF1/CIP1} expression is an early event in gallbladder carcinogenesis and is of prognostic significance for patients with carcinomas of the gallbladder. *Hum Pathol* 32: 771-7, 2001a.
- Li J, Yen C, Liaw D, et al** : PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 275: 1876, 1997.
- Li P, Nicosia SV, Bai W** : Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. *J Biol Chem* 276: 20444-50, 2001.
- Lijovic M, Fabiani ME, Bader J, et al** : Prostate cancer: are new prognostic markers on the horizon?. *Prostate* 3: 62-5, 2000.
- Lindzey J, Kumar MV, Grossman M, et al** : Molecular mechanisms of androgen action. *Vitam Horm* 49: 383-432, 1994.
- Linja MJ, Savinainen KJ, Saramaki OR, et al** : Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. *Cancer Res* 61: 3550-5, 2001.
- Liu Y, Martindale JL, Gorospe M, Holbrook NJ** : Regulation of p21^{WAF1/CIP1} expression through mitogen-activated protein kinase signaling pathway. *Cancer Res* 56: 31-5, 1996.

Lobez F, Belloc F, Lacombe F, et al : Modalities of synthesis of Ki-67 antigen during the stimulation of lymphocytes. *Cytometry* 12: 42-9, 1991.

Loftus JC, Liddington RC : Cell adhesion in vascular biology. New insights into integrin-ligand interaction. *J Clin Invest* 99: 2302, 1997.

Lou W, Ni Z, Dyer K, et al : Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. *Prostate* 42: 239-42, 2000.

Lu X, Toki T, Konishi I, et al : Expression of p21^{WAF1/CIP1} in adenocarcinoma of the uterine cervix. A possible immunohistochemical marker of a favourable prognosis. *Cancer* 82: 2409-17, 1998.

Lundgren R, Nordle O, Josefsson K, and the South Sweden Prostate Cancer Study Group: Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in non-metastatic prostate cancer. A randomized multicenter study with 15 years follow-up. *J Urol* 153: 1580-6, 1995.

IXI

Machen SK, Prayson RA : Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases. *Hum Pathol* 29: 1511-6, 1998.

Macleod KF, Sherry N, Hannon G, et al : Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. *Genes Dev* 9: 935-44, 1995.

Maelandsmo GM, Holm R, Kerbel RS, et al : Cyclin kinase inhibitor p21^{WAF1/CIP1} in malignant melanoma. Reduced expression in metastatic lesions. *Am J Pathol* 149: 1813-22, 1996.

Maki CG, Howley PM : Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. *Mol Cell Biol* 17: 355-63, 1997.

- Marshall WJ** : Latest tests for prostatic neoplasia. J Clin Pathol 51: 347-50, 1998.
- Matrisian LM, Cunha GR, Mohla S** : Epithelial-stromal interactions and tumour progression: meeting summary and future directions. Cancer Res 61: 3844-6, 2001.
- Matsuda T, Junicho A, Tamamoto T, et al** : Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Res Commun 283: 179-87, 2001.
- Matsushima H, Sasaki T, Goto T, et al** : Immunohistochemical study of p21 WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 29: 778-83, 1998.
- Matsushita K, Kobayashi S, Kato M, et al** : Reduced messenger RNA expression level of p21^{CIP1} in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer 69: 259-64, 1996.
- Maygarden SJ, Strom S, Ware JL** : Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma , prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 116: 269-73, 1992.
- Mazzucchelli R, Montironi R, Santinelli A, et al** : Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-9, 2000.
- McDonnall TJ, Troncoso P, Brisbay SM, et al** : Expression of proto-oncogene bcl-2 in the prostate and its association with emergency of androgen-independent prostate cancer. Cancer Res 52: 6940-4, 1992.
- McNeal JE, Gleason DF** : Gleason's classification of prostatic adenocarcinomas. Ann Pathol 11: 163-8, 1991.

- McNeal JE, Villers A, Redwine EA, et al** : Microcarcinoma of the prostate: its association with duct-acinar dysplasia. *Human Pathol* 22:644-52, 1991.
- McNeal JE, Villers AA, Redwine EA, et al** : Capsular penetration in prostate cancer. *Am J Surg Pathol* 14: 240-7, 1990.
- Mettlin CJ, Murphy GP**: Why is the prostate cancer death rate declining in the United States? *Cancer* 82: 249-51, 1998.
- Meyer GE, Yu E, Siegal JA, et al** : Serum basic fibroblast growth factor in men with and without prostate carcinoma. *Cancer* 76: 2304-11, 1995.
- Miyake K, Medina K, Hayashi S, et al** : Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long term bone marrow cultures. *J Exp Med* 171: 477-88, 1998.
- Mohler JL, Partin AW, Epstein JI, et al** : Prediction of prognosis in untreated stage A2 prostatic carcinoma. *Cancer* 69: 511-9, 1992.
- Mokhtar N** : Cancer Pathology Registry, NCI, Al-Asdekaa Press, Cairo, Egypt, 1991.
- Monroe KR, Yui MC, Kolonel LN, et al** : Evidence for an X-linked or recessive genetic component to prostate cancer risk. *Nature Med* 1: 827, 1995.
- Montgomery JS, Price DK, Figg WD** : The androgen receptor gene and its influence on the development and progression of prostate cancer. *J Pathol* 195: 138-46, 2001.
- Montie JE, Pienta KJ** : Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. *Urology* 43: 892, 1994.
- Montironi R, Galluzzi MC, Diamanti L, et al** : Prostatic intraepithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. *Pathol Res Pract* 189: 542-8, 1993.

- Montironi R, Galluzzi MC, Diamanti L, et al** : Prostatic intraepithelial neoplasia. Expression and location of proliferating cell nuclear antigen (PCNA) in epithelial, endothelial and stromal nuclei. *Virchow Arch [A] Pathol Anat* 422:185-92, 1993a.
- Montironi R, Galluzzi MC, Scarpeli M, et al** : Occurrence of cell death (apoptosis) in prostatic intraepithelial neoplasia. *Virchow Arch [A] Pathol Anat* 423:351-7, 1993b.
- Montironi R, Scarpeli M, Sisti S, et al** : Quantitative analysis of prostatic intraepithelial neoplasia on tissue sections. *Anal Quant Cytol Histol* 12: 366-72, 1990.
- Montironi R, Schulman CC**: Precursors of prostatic cancer: progression, regression and chemoprevention. *Eur Urol* 30: 133-7, 1996.
- Mora LB, Buettner R, Ahmad N, et al** : Prostate Adenocarcinoma: Cellular and Molecular Abnormalities. *Cancer Control* 8(6): 551-61, 2001.
- Mora LB, Buettner R, Seigne J, et al** : Constitutive activation of Stat3 in human prostate tumours and cell lines: Inhibitors of Stat3 signaling block growth of prostate cancer cells. *Cancer Res* , 2001a. In press.
- Mora LB, Moscinski LC, Diaz JJ, et al** : Stage B prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. *Cancer Control* 6: 587-91, 1999.
- Morote J, Encabo G, Lopez M, deTorres IM** : Influence of high-grade prostatic intraepithelial neoplasia on total and percentage free serum prostate-specific antigen. *BJU Int* 84: 657-60, 1999.
- Morton RA, Ewing CM, Nagafuchi A, et al** : Reduction of E-cadherin levels and deletion of the α -catenin gene in human prostate cancer. *Cancer Res* 53: 3585, 1993.

Moskaluk CA, Heitmiller R, Zahurak M, et al : p53 and p21^{WAF1/CIP1/SDI1} gene products in barrett oesophagus and adenocarcinoma of oesophagus and oesophagogastric junction. Hum Pathol 27: 1211-20, 1996.

Mousses S, Gokgoz N, Wunder JS, et al : p53 missense but not truncation mutations are associated with low levels of p21^{WAF1/CIP1} mRNA expression in primary human sarcomas. Br J Cancer 84(12): 1635-9, 2001.

Mousses S, Özçelik H, Lee PD, et al : Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4: 1089-92, 1995.

Mucci NR, Akdas G, Manely S, Rubin MA : Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogenous protein expression. Hum Pathol 31(4): 406-14, 2000.

Murphy BC, Pienta KJ, Coffey DS : Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells. Prostate 20: 29, 1992.

Myers RB, Srivastava S, Oelschlager DK, et al : Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86: 1140-4, 1994.

N. LI M, Tsuji K, Kanada Y, et al : Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int 85: 514-8, 2000.

Nagabhushan M, Pretlow TG, Amini SB, et al : Altered expression of CD44 in human prostate cancer during progression. Amer J Clin Pathol 106: 647-51, 1996.

Narod S, Dupont A, Cusan L, et al : The impact of family history on early detection of prostate cancer. *Nature Med* 1: 99, 1995.

Nelson JB, Chan-Tack, Hedican SP, et al : Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. *Cancer Res* 56: 663, 1996.

Nelson JB, Hedican SP, George DJ, et al : Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. *Nature Med* 1: 944, 1995.

Nelson JB, Lee W-H, Nguyen SH, et al : Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. *Cancer Res* 57: 35, 1997.

Newmark JR, Hardy DO, Tonb DC, et al : Androgen receptor gene mutations in human prostate cancer. *Proc Natl Acad Sci USA* 89: 6319, 1992.

Noordzij MA, van Steenbrugge GJ, Schröder FH, Van der Kwast TH : Decreased expression of CD44 in metastatic prostate cancer. *Int J Cancer (Pred Oncol)* 84: 478-83, 1999.

Noordzij MA, van Steenbrugge GJ, Verkaik GJ, et al : The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. *Clin Cancer Res* 3: 805-15, 1997.

Oesterling JE, Suman VJ, Zincke H, Bostwick DG : PSA-detected (clinical stage T1c or BO) prostate cancer. Pathologically significant tumours. *Urol Clin N Am* 20: 687-93, 1993.

Oesterling JU, Fuks Z, Lee CT, Scher HI : Cancer of the prostate. In De Vita VT, Hellman S, Rosenberg SA, eds. *Cancer 'principles and practice of oncology'* 5th edn. Philadelphia, New York : Lippincott Raven Publishers: 1325, 1997.

Ohori M, Wheeler TM, Kattan MW, et al : Prognostic significance of positive surgical margins in radical prostatectomy specimens. *J Urol* 154: 1818-24, 1995.

Okada K, Kojima M, Naya Y, et al : Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. *Urology* 55: 892, 2000.

Okegawa T, Kinjo M, Watanabe H, et al : The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/ml. *BJU Int* 85: 708-14, 2000.

Oppenheimer JR, Epstein JI : Partial atrophy in prostate needle cores- another diagnostic pitfall for the surgical pathologist. *Am J Surg Pathol* 22: 440-5, 1998.

Orlando C, Gelmini S, Selli C, et al : Telomerase in urological malignancy. *J Urol* 166: 666-73, 2001.

Orozco RE, Kunnel BS, O'Dowd G, Stamey TA: Positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination: *Urology* 51: 531-3, 1998.

P

Pacelli A, Bostwick DG: The clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. *Urology* 50:355-9, 1997.

Paget S : The distribution of secondary growth in cancer of the breast. *Lancet* 1: 571-3, 1989.

Palazzo JP, Kafka NJ, Grasso L, et al : The role of p53, p21^{WAF1/CIP1}, and bcl-2 in radioresistant colorectal carcinoma. *Hum Pathol* 28: 1189-95, 1997b.

- Palazzo JP, Mercer WE, Kovatich AJ, McHugh M :** Immunohistochemical localization of p21^{WAF1/CIP1} in normal, hyperplastic, and neoplastic uterine tissues. *Hum Pathol* 27: 60-6, 1997a.
- Paradis V, Eschwège P, Loric S, et al :** De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. *J Clin Pathol* 51: 798-802, 1998.
- Park S, Shinohara K, Grossfeld GD, et al :** prostate cancer detection in men with prior high-grade prostatic intraepithelial neoplasia or atypical prostate biopsy. *J Urol* 165: 1409-14, 2001.
- Parker SB, Eichele G, Zhang P, et al :** p53-independent expression of p21^{Cip1} in muscle and other terminally differentiating cells. *Science* 267: 1024-7, 1995.
- Parker SL, Tong T, Bolden S, et al :** Cancer statistics. *Cancer J Clin* 46: 5-27, 1996.
- Partin AW, Murphy GP, Brawer MK, et al :** Report on prostate cancer tumour marker workshop 1999. *Cancer* 88: 955-63, 2000.
- Partin AW, Subong E, Walsh PC, et al :** Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. *JAMA* 277: 1445, 1997.
- Paul R, Ewing CM, Jarrard DF, Isaacs WB :** The cadherin cell-cell adhesion pathway in prostate cancer progression. *Br J Urol* 79(suppl): 37, 1997.
- Paulson DF:** Stage A prostatic adenocarcinoma. *World J Urol* 7: 34-7, 1989.

- Peehl DM, Skowronski RJ, Leung GK, et al :** Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. *Cancer Res* 54: 805, 1994.
- Perrotti M, Rabbani F, Farkas A, et al:** Early detection and potential for surgical cure in poorly differentiated prostate cancer 1973-94: observations from the surveillance, Epidemiology and End Results database. *J Urol* 160: 811-5, 1998.
- Perrotti M, Rabbani F, Russo P, et al:** Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumours. *Urology* 52: 106-10, 1998a.
- Petein M, Michel P, Van Velthoven R, et al :** Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. *Am J Clin Pathol* 96: 628-34, 1991.
- Pienta KJ, Esper PS :** Risk factor for prostate cancer. *Ann Intern Med* 118: 793, 1993.
- Pietiläinen T, Lipponen P, Aaltomaa S, et al :** The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. *J Cancer Res. Clin Oncol* 122: 687-92, 1996.
- Pietrzkowski Z, Wernicke D, Porcu P, et al :** Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor1. *Cancer Res* 52: 6447-51, 1992.
- Poteat HT, Ho GT, Lee M-L T, et al :** The utility of patient age in evaluating prostate cancer. *J Clin Pathol* 107: 337-44, 1997.
- Prall F, Nollau P, Neumaier M, et al :** CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of human tissues. *J Histochem Cytochem* 44: 35, 1996.

Q

Qian J, Wollan P, Bostwick DG: The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. *Human Pathol* 28:143-8, 1997.

Qin L, Ng IO : Expression of p27^{KIP1} and p21^{WAF1/CIP1} in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. *Hum Pathol* 32: 778-84, 2001.

R

Rabbani F, Stroumbakis N, Kava BR, et al : Incidence and clinical significance of false-negative sextant prostate biopsies. *J Urol* 159: 1247-50, 1998.

Rajan R, Vanderslice R, Kapur S, et al : Epidermal growth factor(EGF) promotes chemomigration of a human prostate tumour cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. *Prostate* 28:1, 1996.

Randolf TL, Amin MB, Ro JY, Ayala AG: Histological variants of adenocarcinomas of the prostate: pathological criteria and clinical significance. *Mod Pathol* 10: 612, 1997.

Ravery V, Szabo J, Toubanc M, et al : A single positive prostate biopsy in six does not predict a low-volume prostate tumour. *Br J Urol* 77: 724-8, 1996.

Raviv G, Janssen Th, Zlotta AR, et al : Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. *J Urol* 156:1050-5, 1996.

Raviv G, Zlotta AR, Janssen Th, et al : Does prostate-specific antigen and prostate-specific antigen density enhance the detection of prostate cancer in patients initially diagnosed to have prostatic intraepithelial neoplasia? *Cancer* 77:2103-8, 1996a.

- Reber S, Matzku S, Günthert U, et al** : Retardation of metastasis tumour growth after immunisation with metastasis- specific monoclonal antibodies. *Int J Cancer* 46: 919-27, 1990.
- Rey MJ, Fernandez PL, Jares P, et al** : p21^{WAF1/CIP1} is associated with cyclin D1^{CCND1} expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. *J Pathol* 184: 365-71, 1998.
- Riparbelli MG, Callaini G, Tripodi SA, et al** : Localization of the bcl-2 protein to the outer mitochondrial membrane by electron microscopy. *Exp Cell Res* 221: 363-9, 1995.
- Robbins SE, Shu WP, Kirschenbaum A, et al** : Bone extracellular matrix induces homebox proteins independent of androgens: possible mechanism of androgen independent growth in human prostate cancer cells. *Prostate* 29: 362, 1996.
- Ross RK, Bernstein L, Lobo RA, et al** : 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. *Lancet* 339: 887, 1992.
- Rudolph P, Kellner U, Chassevent A, et al** : Prognostic relevance of a novel proliferation marker, Ki-s11, for soft-tissue sarcoma- a multivariate study. *Am J Pathol* 150: 1997-2007, 1997.
- Rudzki Z, Jothy S** : CD44 and the adhesion of neoplastic cells. *J Clin Pathol: Mol Pathol* 50: 57-71, 1997.
- Ruijter ET, van de Kaa CA, Schalken JA, et al** : Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. *J Pathol* 180: 295-9, 1996.
- Ruijter ET, van Leenders G, Miller G, et al** : Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors. *J Pathol* 192: 229-33, 2000.

Saegusa M, Hashimura M, Machida D, Okayasu I : Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours. *J Pathol* 187: 173-83, 1999a.

Saegusa M, Machida D, Hashimura M, Okayasu I : CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. *J Pathol* 189: 326-37, 1999.

Sakr WA, Haas GP, Cassin BJ, et al : Frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, *J Urol* 150: 379-85, 1993.

Sakr WA, Haas GP, Grignon DJ, et al : High-grade prostatic intraepithelial neoplasia (HG prostatic intraepithelial neoplasia) and prostatic adenocarcinoma between the ages of 20-69. An autopsy study of 249 cases. *In Vivo* 8: 439-44, 1994.

Sakr WA, Partin AW: Histological markers of risk and the role of High-grade prostatic intraepithelial neoplasia. *Urology* 57: 115-20, 2001.

Sakr WA, Ward C, Grignon DJ, et al : Epidemiology and molecular biology of early prostatic neoplasia. *Mol Urol* 4: 109-13, discussion 115, 2000.

Salvesen GS, Dixit VM : Caspases: Intracellular signaling by proteolysis. *Cell* 91: 443-6, 1997.

Sasaki K, Sato T, Kurose A, et al : Immunohistochemical detection of p21WAF1/CIP1/SDI1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. *Hum Pathol* 27: 912-6, 1996.

Sasor A, Wagrowska-Danilewicz M, Danilewicz M : Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions.

Immunohistochemical quantitative study. *Pol J Pathol* 51: 31-6, 2000.

Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer . The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. *Cancer* 72: 2031-40, 1993.

Schultz DS, Amin MB, Zarbo RJ : Basement membrane type IV collagen immunohistochemical staining in prostatic neoplasia. *Appl Immunohistochem* 1:123-6, 1993.

Schwaller J, Koeffler HP, Nikalaus G, et al : Posttranscriptional stabilization underlies p53-independent induction of p21 in differentiating human leukemic cells. *J Clin Invest* 95: 937-9, 1995.

Sehdev AES, Pan CC, Epstein JI : Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (stage T1c) prostatic adenocarcinoma. *Hum Pathol* 32(5): 494-9, 2001.

Seiter S, Arch R, Reber S, et al : Prevention of tumour metastasis formation by anti-variant CD44. *J Exp Med* 177: 443-55, 1993.

Sgrignoli AR, Walsh PC, Steinberg GD, et al : Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to benefit from radical surgery. *J Urol* 152: 1077-81, 1994.

Sheikh MS, Rochefort H, Garcia M : Overexpression of p21^{WAF1/CIP1} induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. *Oncogene* 11: 1899-1905, 1995.

Shepherd D, Keetch DW, Humphrey P, et al : Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. *J Urol* 156:460-3, 1996.

Sherr CJ : Cancer cell cycles. *Science* 274: 1672-7, 1996.

- Sherr CJ, Roberts JM** : Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes&Dev* 9: 1149-63, 1995.
- Shi Y-Z, Hui A-M, Takayama T, et al** : Reduced p21^{CIP1/WAF1} protein expression is predominantly related to altered p53 in hepatocellular carcinomas. *Br J Cancer* 83: 50-5, 2000.
- Shibata H, Spencer TE, Onate SA, et al** : Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. *Rec Prog Horm Res* 52: 141-64, 1997.
- Shim JW, Shin HS, Ahn HK, et al** : Proteinase Expression in PIN: An immunohistochemical study of uPA, CD, and MMPs. *J Urol Pathol* 12: 93-104, 2000.
- Shiohara M, El-Deiry WS, Wada M, et al** : Absence of WAF1 mutations in a variety of human malignancies. *Blood* 84: 3781-4, 1994.
- Silberman MA, Partin AW, Veltri RW, Epstein JI** : Tumour angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. *Cancer* 79: 772-9, 1997.
- Singh A, Jones RF, Friedman H, et al** : Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. *Anticancer Res* 19: 5417, 1999.
- Singh RK, Llansa N, Bucana CD, et al** : Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. *Cell Growth Differ* 7: 397-404, 1996.
- Skjorten FJ, Brener A, Harvi S, et al** : Prostatic intraepithelial neoplasia on surgical resections: Relationship to coexistent carcinoma and atypical adenomatous hyperplasia of the prostate. *Cancer* 79(6): 1172-9, 1997.

- Sleeman J, Moll J, Sherman L, et al** : The role of CD44 splice variants in human metastatic cancer. In: Cell adhesion and human disease. Chichester: Wiley :142-56, 1995.
- Smith JR, Freije D, Carpten JD, et al** : Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371, 1996.
- Smith MR, Kantoff PW** : Molecular Biology of Prostate Cancer. In Mendelsohn J, Howley PM, Israel MA, Liotta LA eds. The molecular basis of cancer 2nd ed. Philadelphia London New York: WB Saunders Company: 344, 2001a.
- Smith MR, Kantoff PW** : Molecular Biology of Prostate Cancer. In Mendelsohn J, Howley PM, Israel MA, Liotta LA eds. The molecular basis of cancer 2nd ed. Philadelphia London New York: WB Saunders Company: 343-360, 2001.
- Sneath RJS, Mangham DC** : The normal structure and function of CD44 and its role in neoplasia. J Clin Pathol: Mol Pathol 51: 191-200, 1998.
- Sobin LH, Wittekind C (eds)**: TNM classification of malignant tumours (5th ed), Wiley-Liss, New York, 1997.
- Spitz MR, Strom SS, Yamamura Y, et al** : Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer (Pred Oncol) 89: 259-64, 2000.
- Stackhouse GB, Sesterhenn IA, Bauer JJ, et al** : p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162: 2046-7, 1999.
- Stamey T** : Making the most out of six systematic sextant biopsies. Urology 45: 2-12, 1995.

Stamey TA, McNeal JE, Yemoto CM, et al : Biological determinants of cancer progression in men with prostate cancer. JAMA 281: 1395, 1999.

Stamey TA, Yemoto CM, McNeal JE, et al : Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 163: 1155-60, 2000.

Stanford JL, Just JJ, Gibbs M, et al : Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 119, 1997.

Stattin P, Damber JE, Karlberg L, Bergh A : Cell proliferation assessed by Ki-67 immunoreactivity on formalin-fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157: 219, 1997.

Stearns ME, Garcia FU, Fudge K, et al : Role of interleukin 10 and transforming growth factor beta 1 in the angiogenesis and metastasis of human prostate primary tumour lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5: 711-20, 1999.

Stearns ME, Rhim J, Wang M, et al : Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion . Clin Cancer Res 5: 189-96, 1999a.

Steck PA, Perhouse MA, Jasser SA, et al : Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356, 1997.

Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI : Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21: 566-76, 1997.

Strickler HJ, Ruddock LJ, Wan J, Belville WD : Detection of non-palpable prostate cancer. A mathematical and laboratory model. Br J Urol 142: 43-6, 1993.

Strohmeyer D, Rossing C, Strauss F, et al : Tumour angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42: 26-33, 2000.

Sugamoto T, Tanji N, Nishio S, Yokoyama M : Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma. Oncol Rep 6: 519-22, 1999.

Sugamoto T, Tanji N, Sato K, et al : The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma : correlation with neovascularization. Anticancer Res 21: 77-88, 2001.

Sugimura Y, Cunha GR, Hayword S, et al : Keratinocyte growth factor (KGF) is a mediator of testosterone induced prostatic development. J Urol 151: 381A, 1994.

Tachibane M, Miyakawa A, Nakamura K, et al : Role of proliferative activity estimated by bromodeoxyuridine labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumours. J Urol 156: 63-9, 1996.

Tafilli MV, Gheiler EL, Tiguert R, et al : Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 53: 372, 1999.

Takahashi H, Furusato M, Allsbrook WC Jr, et al : Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from japanese men. Cancer Res 55: 1621-4, 1995.

Takahashi H, Ichimiya S, Nimura Y, et al : Mutation allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. *Cancer Res* 58: 2076-7, 1998.

Takayama H, Shin M, Nonomura N, et al : p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens from non-transition and transition zones. *Jpn J Cancer Res* 91: 941-7, 2000.

Takeichi M : Cadherin cell adhesion receptors as a morphogenic regulator. *Science (Washington DC)* 251: 1451-5, 1991.

Tamboli P, Amin MB, Xu HJ, et al : Immunohistochemical expression of retinoblastoma and p53 tumour suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. *Mod Pathol* 11: 247-52, 1998.

Tang DG, Potter AT : Target to apoptosis: a hopeful weapon for prostate cancer. *Prostate* 32: 284, 1997.

Taplin ME, Bubley GJ, Shuster TD, et al : Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *N Engl J Med* 332: 1393-8, 1995.

Terris MK, Haney DJ, Johnstone IM, et al : Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. *Urology* 45: 75-80, 1992.

Thompson D, Bartels PH, Bartels HG, Montironi R : Knowledge-guided histometry of the basal cell layer in prostatic intraepithelial neoplasia. *Anal Quant Cytol Histol* 18: 177-84, 1996.

Thompson TC, Truong LD, Timme TL, et al : Transforming growth factor beta 1 as a biomarker for prostate cancer. *J Cell Biochem Suppl* 16H: 54-61, 1992.

- Thorson P, Vollmer RT, Arcangeli C, et al** : Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. *Mod Pathol* 11: 543-51, 1998.
- Tilley WD, Buchanan G, Hickey TE, et al** : Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. *Clin Cancer Res* 2: 277, 1996.
- Tolg C, Hofman M, Herrlich P, Ponta H** : Splicing choice from ten variant exons establishes CD44 variability. *Nucleic Acids Res* 21: 1225-9, 1993.
- Tominaga S, Kuroishi T** : An ecological study on diet/ nutrition and cancer in Japan. *Int J Cancer Suppl* 10: 2-6, 1997.
- Trapman J, Brinkmann AO** : The androgen receptor in prostate cancer. *Pathol Res Pract* 192: 752-60, 1996.
- Trochon V, Mabilat C, Bertrand P, et al** : Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. *Int J Cancer* 66: 664-8, 1996.
- Tsai MJ, O'Malley BW** : Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 63: 451-86, 1994.
- Tu H, Jacobs SC, Borkowski A, Kyprianou N** : Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF- β 1 and bcl-2 expression. *Int J Cancer* 69: 357, 1996.
- Tulinius H, Egilsson V, Olafsdottir CH, et al** : Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. *Br Med J* 305: 855, 1992.
- Tzonou A, Signorello LB, Lagiou P, et al** : Diet and cancer of the prostate: a case-control study in greece. *Int J Cancer* 80: 704-8, 1999.

U

Ueda T, Ichikama T, Tamura J, et al : Expression of KAI1 protein in benign and prostatic hyperplasia and prostate cancer. *Am J Clin Pathol* 149: 1435, 1996.

Ulbright TM : Testis risk and prognostic factors. The pathologist's perspective. *Urol Clin North Am* 26: 611-26, 1999.

Underhill C : CD44: the hyaluronan receptor. *J Cell Sci* 103: 293-8, 1992.

V

Vaillancourt L, Tetu B, Fradet Y, et al : Effect of nonadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostate carcinoma. A randomized study. *Am J Surg Pathol* 20:86-93, 1996.

Van Diest PJ, Brugal G, Baak JPA : Proliferation markers in tumours: interpretation and clinical value. *J Clin Pathol* 51: 716-24, 1998.

van Weering D, Baas P, Bos J : A PCR-based method for the analysis of human CD44 splice products. *PCR Methods Appl* 3: 100-6, 1994.

Verkaik NS, Trapman J, Romijn JC, et al : Downregulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. *Int J Cancer* 80: 439-43, 1999.

Viale G, Pellegrini C, Mazzarol G, et al : p21^{WAF1/CIP1} expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. *J Pathol* 187: 302-7, 1999.

Victorzon M, Roberts PJ, Haglund C, et al : Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. *Oncology* 53: 182-91, 1996.

Visakorpi T, Hyytinen E, Koivisto P, et al : In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nature Genet* 9: 401, 1995.



- Waler G, Ludvigsen TC, Stenwig AE:** Prognosis of incidental prostatic cancer in Aust-Agder county, Norway. *Eur Urol* 18: 179-83, 1990.
- Wakasugi E, Kobayashi T, Tamaki Y, et al :** p21(WAF1/CIP1) and p53 protein expression in breast cancer. *Am J Clin Pathol* 107: 684-91, 1997.
- Walsh K, Sherwood RA, Dew TK, Mulvin D :** Angiogenic peptides in prostatic disease. *Br J Urol* 84: 1081-3, 1999.
- Wang X, Brannigan RE, Redemaker AW, et al :** One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen . 158: 1431-5, 1997.
- Warner J, Whitmore WF Jr:** Expectant management of clinically localized prostatic cancer. *J Urol* 152: 1761-5, 1994.
- Watson RWJ, Fitzpatrick JM :** Target sites for manipulating apoptosis in prostate cancer. *Br J Urol Int* 85(suppl): 38-44, 2000.
- Weinberg RA :** The retinoblastoma protein and cell cycle control. *Cell* 81: 323, 1995.
- Weingartner K, Ben-Sasson SA, Stewart R, et al :** Endothelial cell an in vitro model for assessment. *J Urol* 159: 465-70, 1998.
- Whitmore WF:** Natural history of low-stage prostatic cancer and the impact of early detection. *Urol Clin N Am* 17: 689-97, 1990.
- Winkstrom P, Stattin P, Franck-Lissbrant I, et al :** Transforming growth factor- β 1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. *Prostate* 37: 19-29, 1998.
- Wilcox G, Soh S, Chakraborty S, et al :** Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. *Hum Pathol* 29 (10): 1119-23, 1998.

Wills ML, Hamper UM, Partin Aw, Epstein JI : Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. *Urology* 49: 367-73, 1997.

Wilson JD, Griffin JE, Russell DW: Steroid 5-alpha reductase 2 deficiency. *Endocrine Rev* 14:577,1993.

X

Xie W, Wong YC, Tsao SW : Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. *Prostate* 15;44: 31-9, 2000.

Xiong Y, Hannon GJ, Zhang H, et al : p21 is a universal inhibitor of cyclin kinases. *Nature* 366: 701-4, 1993.

Y

Yan G, Fukabori Y, McBride G, et al : Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. *Mol Cell Biol* 13: 4513-22, 1993.

Yan G, Fukabori Y, Nikolaropoulos S, et al : Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin *Mol Endocrinol* 6: 2123-8, 1992.

Yan G, Wang F, Fukabori Y, et al : Expression and transforming activity of a variant of the heparin-binding fibroblast growth factor receptor gene resulting from splicing of the alpha exon at an alternate 3-acceptor site. *Biochem Biophys Res Commun* 183: 423-30, 1992a.

Yang B, Yang BL, Savani RC, et al : Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. *EMBO J* 13: 286-96, 1994.

Yang RM, Naitoh J, Murphy M, et al : Low p27 expression predicts poor disease-free survival in patients with prostate cancer. *J Urol* 159: 941-5, 1998.

Yang Y, Hao J, Liu X, et al : Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. *Am J Pathol* 150: 693-704, 1997.

Yohn jj, Smith C, Stevens T, et al : Autoregulation of endothelin-1 secretion by cultured human keratinocytes via the endothelin B receptor. *Biochem Biophys Acta* 1224: 454, 1994.

Yu D, Liu F, Liang Z : Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder [Chinese]. *Zhonghua Bing Li Xue Za Zhi* 25: 202-5, 1996.

Zagars GK: Prostate-specific antigen as outcome variable for T1 and T2 prostate cancer treated by radiation therapy. *J Urol* 152: 1786, 1994.

Zakian VA : Telomeres: beginning to understand the end. *Science* 270: 1601, 1995.

Zeitman AL, Edelstein RA, Coen JJ, et al : Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathological findings on biochemical disease -free outcome. *Urology* 43:828, 1994.

Zetter B : Adhesion molecules in tumour metastasis. *Semin Cancer Biol* 4: 219-29, 1993.

Zhang H, Hannon GJ, Beach D : p21-containing cyclin kinases exist in both active and inactive states. *Genes Dev* 8: 1750-8, 1994.

Zhong H, De Marzo AM, Laughner E, et al : Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. *Cancer Res* 59: 5830-5, 1999.

Zi X, Grasso AW, Kung H-J, Agarwal R : A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-

dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. *Cancer Res* 58: 1920-9, 1998.

Zöller M : CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. *J Mol Med* 73: 425-38, 1995.